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Abstract
The HIV-1 Rev trans-activator is a nucleocytoplasmic shuttle protein that is essential for virus replication. Rev directly binds
to unspliced and incompletely spliced viral RNA via the cis-acting Rev Response Element (RRE) sequence. Subsequently, Rev
oligomerizes cooperatively and interacts with the cellular nuclear export receptor CRM1. In addition to mediating nuclear
RNA export, Rev also affects the stability, translation and packaging of Rev-bound viral transcripts. Although it is established
that Rev function requires the multimeric assembly of Rev molecules on the RRE, relatively little is known about how many
Rev monomers are sufficient to form a trans-activation competent Rev:RRE complex, or which specific activity of Rev is
affected by its oligomerization. We here analyzed by functional studies how homooligomer formation of Rev affects the
trans-activation capacity of this essential HIV-1 regulatory protein. In a gain-of-function approach, we fused various
heterologous dimerization domains to an otherwise oligomerization-defective Rev mutant and were able to demonstrate
that oligomerization of Rev is not required per se for the nuclear export of this viral trans-activator. In contrast, however, the
formation of Rev oligomers on the RRE is a precondition to trans-activation by directly affecting the nuclear export of Rev-
regulated mRNA. Moreover, experimental evidence is provided showing that at least two protein activation domains are
required for the formation of trans-activation competent Rev:RRE complexes. The presented data further refine the model of
Rev trans-activation by directly demonstrating that Rev oligomerization on the RRE, thereby recruiting at least two protein
activation domains, is required for nuclear export of unspliced and incompletely spliced viral RNA.
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Introduction
The Rev trans-activator of human immunodeficiency virus type
1 (HIV-1) is essential for virus replication (reviewed in [1]). Rev is
a small RNA-binding phosphoprotein of 116 amino acids (aa) that
constantly shuttles between the nuclear and cytoplasmic compart-
ments of infected cells [2–8]. The main function of Rev is to
mediate the nuclear export of unspliced and incompletely spliced
viral transcripts, either encoding the structural proteins and
enzymes Gag, Pol and Env or serving as genomic RNA [9–12]. In
addition to promoting nuclear RNA export, Rev has also been
shown to affect the stability and translation of viral transcripts
[10,13–16]. Moreover, more recent studies have provided
evidence that Rev also counteracts HIV-1 integration and
facilitates the packaging of the viral RNA genome (for recent
reviews see [17,18]).
The structure of Rev is characterized by an organization
composed of distinct functional regions. Nuclear import and RNA
recognition is mediated by a short stretch of amino acids rich in
basic residues [19–23]. This RNA binding domain (RBD) spans aa
residues 33–46 in Rev’s amino terminal region. A protein
activation domain, harbouring a leucine-rich nuclear export signal
(NES) at aa residues 78–84, is located in the protein’s carboxy
terminal region [24–28]. By specifically accessing the cellular
CRM1 export pathway, this NES mediates the nucleocytoplasmic
translocation of Rev-containing ribonucleoprotein (RNP) com-
plexes across the nuclear envelope [12,29–32]. Finally, sequences
flanking the RBD have been demonstrated to constitute a domain
required for the formation of homooligomeric Rev complexes [33–
35]. Detailed biophysical studies suggested that this region forms
an amino-terminal amphipathic helix-turn-helix motif [36,37].
The cis-acting target site of Rev on viral RNA is a complex
stem-loop structure of 351 nucleotides (nt), termed the Rev
Response Element (RRE), that is located in the env gene [2–5,38–
44]. The RRE contains a single, primary, high-affinity Rev
binding site, termed stem-loop IIB (SLIIB) [45–48]. The initial
binding of a single Rev molecule to the SLIIB element initiates the
oligomerization of Rev proteins through cooperative assembly
along the RRE [41,49–54]. In fact, in vitro the occupation of the
RRE by as many as 13 Rev molecules has been reported [41,49–
51,53]. The mechanism of the cooperative assembly of Rev
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hydrophobic regions (referred to as ‘‘head’’ and ‘‘tail’’) in Rev that
form a series of symmetrical head-to-head and tail-to-tail
protein:protein interactions [35]. Although it is well established
that this self-association of Rev on the RRE is required for Rev
trans-activation [22,33,34,55,56], it is still unknown how many Rev
molecules are sufficient to create a trans-activation competent
Rev:RRE RNA complex. Attempts to answer this question are
hampered by the fact that Rev is characterized by a strong and
uncontrolled tendency to self-associate in solution, a process that is
not required for Rev function but may compromise the formation
of higher Rev:RRE complexes in in vitro experiments [47,57–60].
Therefore, we used here cell-based functional studies to analyze in
detail the effect of Rev homooligomer formation on trans-
activation mediated by this essential HIV-1 regulatory protein.
Results
Functional Rescue of a Multimerization-deficient Rev
Mutant by Fusion to Heterologous Dimerization Domains
Prior to selecting an oligomerization-deficient Rev mutant for
further analyses various functional aspects of Rev had to be
considered. The dependence of Rev’s function on the formation of
Rev oligomers on the RRE implies that the expression of an
oligomerization-deficient Rev mutant should exert a dominant-
negative (i.e. trans-dominant) phenotype over the wildtype (WT)
protein. A classical NES-deficient trans-dominant Rev mutant such
as, for example, the RevM10 protein [19] (Figure 1A), is able to
occupy Rev’s primary binding site SLIIB or, alternatively, can be
recruited into nascent Rev homooligomeric complexes on the
RRE by protein:protein interaction with wildtype Rev [61]
(Figure 1B). In contrast, oligomerization-defective Rev mutants
are able to block the SLIIB, but cannot obstruct higher order
complexes composed of wildtype Rev molecules (Figure 1B). Thus,
when directly compared, the trans-dominant phenotype of an
oligomerization-defective Rev mutant is less pronounced as
opposed to the phenotype of an export-deficient mutant (e.g.
RevM10). A frequently overlooked aspect is the fact that Rev
mutants that are deficient in their capacity to oligomerize on the
RRE have been typically identified in vitro using purified
components. However, in living cells homooligomer formation
by these Rev mutants may still occur. For example, the frequently
analyzed RevM4 mutant protein (YSN to DDL at aa position
23,25,26) has been reported to be multimerization-deficient in vitro
[33], but forms to a significant extent homooligomeric complexes
on RRE RNA in vivo [55]. In agreement with the latter finding,
RevM4 is not able to block Rev function in a trans-dominant
manner [34,55], which, as outlined above, should be the case for
a bona fide oligomerization-defective mutant. Therefore, for our
following detailed analyses we selected the previously described
mutant RevSLT40, that is characterized by two missense
mutations in Rev’s amino-terminal hydrophobic region (IL to
DD at aa position 59,60; see Figure 1A) [34]. Importantly, the aa
residues I59 and L60 were previously identified by a combination
of genetic and biochemical screens as being important for the
molecular interactions that mediate the multimeric assembly of
Rev on the RRE [35]. Furthermore, in an independent study it
has been shown that RevSLT40 is a trans-dominant inhibitor of
Figure 1. HIV-1 Rev mutants and phenotypes. (A) The RNA binding domain/nuclear localization signal (RBD) is flanked by amino acid sequences
that constitute the multimerization interface (M). The nuclear export signal (NES) is located in Rev’s carboxy terminus. The protein name, the positions
mutated within the 116-amino acid (aa) Rev protein, the aa changes introduced and the resulting phenotypes are indicated. (B) Schematic
representation of Rev:RRE complex formation. Oligomerization of Rev wildtype (WT) molecules on the RRE is essential for trans-activation. A nuclear
export-defective Rev mutant (RevM10) exerts a more pronounced trans-dominant phenotype when compared to an oligomerization-defective
protein (RevSLT40). For details see text.
doi:10.1371/journal.pone.0038305.g001
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inability to form oligomeric complexes on the RRE in vitro and in
vivo [34]. Thus, RevSLT40 fulfills all criteria of an oligomeriza-
tion-defective Rev protein.
Rev’s capacity to form oligomers on the RRE may directly
affect a distinct Rev activity (e.g. the binding, stabilization, nuclear
export or translation of target RNAs). To assess this functional
aspect in more detail we initially set out to restore the biological
activity of RevSLT40 by engineering a variant in which a di-
merization interface was provided by a heterologous sequence. For
this, sequences encoding the leucine zipper domain of the yeast
transcription factor GCN4, which has been shown to form stable
dimers [62,63], and RevSLT40 were fused.
We first employed an established reporter gene-based in vivo
RNA binding assay [55,64] to confirm that the respective
ZipRevSLT40 protein is able to recognize RRE RNA. The
pSLIIB/CAT reporter construct contains the CAT gene under the
transcriptional control of the HIV-1 LTR promoter (depicted in
Figure 2A). The wildtype TAR element, which is the promoter-
proximal RNA target sequence of the HIV-1 Tat transcriptional
trans-activator, is replaced by a sequence encoding the RRE-
derived SLIIB high-affinity Rev binding site. This promoter is only
activated by Tat-Rev fusion proteins and is not responsive to Tat
or Rev alone [64]. Thus, the quantity of CAT produced gives an
indication of the RNA binding ability of a given Rev mutant.
As expected, the cotransfection of HeLa cells with an unrelated
vector or with expression vectors encoding HIV-1 Tat or Rev did
not result in trans-activation of the pSLIIB/CAT reporter
construct (Figure 2B). A detectable level of CAT activity was
observed when an expression plasmid encoding a Tat-Rev fusion
protein was included in the transfection, serving as positive
control. This promoter activation was not detected when the
SLIIB binding-incompetent Tat-RevM5 mutant protein [55] was
used as negative control. However, the coexpression of constructs
carrying the SLT40 mutation (see Figure 1A) clearly resulted in
elevated CAT levels, indicating binding of the respective Tat-Rev
fusion proteins to the RRE SLIIB site in vivo.
Further, we analyzed the trans-activation capacity of the
ZipRevSLT40 fusion protein in various functional assays. First,
protein expression in transfected HeLa cells was confirmed by
Rev-specific Western blot analysis (Figure 3A). Next, we employed
a widely used standard Rev assay that is based on the Rev-
responsive reporter construct pDM128/CMV [21,26]. This
construct contains the CAT gene and the RRE sequence, both
of which are positioned between HIV-1 splice sites and are under
the control of the cytomegalovirus immediate-early promoter.
Thus, unspliced CAT encoding transcripts are exported out of the
Figure 2. In vivo RNA binding by Rev mutants. (A) Schematic representation of the pSLIIB/CAT reporter used to analyze Rev:RRE RNA binding in
vivo. (B) In vivo RRE RNA-binding phenotypes of various trans-activators are shown. HeLa cells were transiently cotransfected with the Rev reporter
construct pSLIIB/CAT, pBC12/CMV/b-Gal (internal control) and the indicated Tat-Rev fusion constructs. At 48 h post-transfection, CAT and b-Gal
expression was analysed by ELISA. CAT values were adjusted for transfection efficiency to the b-Gal level in each culture. Data are expressed as
a percentage of wildtype Rev activity (set to 100%).
doi:10.1371/journal.pone.0038305.g002
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resulting in elevated levels of CAT expression. As shown, the
nuclear export-deficient control RevM10 as well as the oligomer-
ization-defective mutant RevSLT40, was, as reported previously
[19,34], inactive in this assay (Figure 3B). However, when
compared to the biological activity of the Rev wildtype (RevWT)
protein the in-frame fusion of the GCN4 leucine zipper to
RevSLT40 notably restored Rev function.
Since Rev acts in reality on full-length (i.e. unspliced) and
incompletely spliced HIV-1 RNA, we next wanted to test Rev
trans-activation in the viral context. Therefore we cotransfected
HeLa cells with the same Rev expression vectors as before,
together with a HIV-1 proviral DNA that was mutated in the rev
gene (HIVDrev) [65]. The capacity of the various Rev mutants to
rescue in trans the replication of this defective provirus was
subsequently analyzed by monitoring the accumulation of HIV-1
p24
Gag antigen in the respective culture supernatants. The data
that were obtained in these experiments closely resembled the
results that were obtained by using the more artificial CAT
reporter construct (Figure 3B). Again, the RevSLT40 or RevM10
mutants were inactive in this assay, while expression of the
ZipRevSLT40 fusion protein resulted in the release of detectable
amounts of virus particles, although not to the same extent as seen
with RevWT (Figure 3C).
To directly confirm leucine zipper-dependent interaction of Rev
in transfected cells we employed a flow cytometry-based FRET
assay system [66]. COS cells were transiently transfected with
vectors encoding Rev fusion proteins that were tagged at their
carboxy terminus either with a donor or an acceptor fluorophore
(CFP or YFP, respectively). The transfection protocol also
included the GPV-RRE reporter vector, that contains the HIV-
1 gag-pol gene and expresses Gag proteins in a Rev-dependent
fashion [67]. At 24 h post-transfection, Western blot analyses
revealed the expected Rev phenotypes. Significant amounts of
Gag proteins were only detectable in the cultures in which either
RevWT or ZipRevSLT40 proteins were expressed, but not in case
of RevSLT40 (Figure 4A). FACS-FRET analysis on cell cultures
which were transfected in parallel revealed that coexpression of
CFP and YFP labelled RevWT resulted in 80.3% of FRET
positive cells which fell within the background adjusted gate,
indicating pronounced Rev:Rev interaction (Figure 4B and 4C).
As expected, the RevSLT40 mutant did not produce a significant
FRET signal (2.8%), while expression of ZipRevSLT40 yielded
41.9% of FRET positive cells.
Finally, to further support the preceding results we also wanted
to confirm the reconstitution of Rev activity by using another
independent technical approach. The ARGENT regulated homo-
dimerization kit (ARIAD Pharmaceuticals) employs cell permeant
ligands (e.g. the chemical homodimerizer molecule AP20187) that
allow the induction of dimerization of proteins that contain the FK
binding protein (FKBP) motif (e.g. FKBP-Rev fusions). Therefore
we generated FKBP-RevWT and FKPB-RevSLT40 encoding
expression vectors and analyzed them as before (Figure 5A and
5B). These experiments confirmed that the formation of
RevSLT40 homodimers is able to rescue replication of HIV-1 to
a level of ,50% of RevWT activity. Obviously, this effect was only
observed in presence of the chemical homodimerizer (Figure 5B).
Taken together, the combined data suggest that the biological
activity of an otherwise oligomerization-defective Rev mutant can
be restored to a significant extent by in-frame fusion of this mutant
protein to a heterologous dimerization motif.
Figure 3. Analysis of Rev trans-activation. (A) Expression of Rev
wildtype and mutants. HeLa cells were transiently transfected with
constructs expressing the indicated Rev constructs and cell extracts
were prepared at 48 h post-transfection for Rev- and tubulin-specific
(gel loading control) Western blot analysis. (B) Biological activity of
various Rev proteins. HeLa cells were transiently transfected with the
CAT expressing Rev reporter pDM128/CMV, the indicated Rev
expression vectors and pBC12/CMV/b-Gal DNA (internal transfection
control). At 48 h post-transfection Rev trans-activation was analyzed by
CAT-specific ELISA. All CAT values were adjusted for transfection
efficiency to the internal b-Gal level and compared to Rev wildtype
activity (arbitrarily set to 1.0); WT, wildtype Rev. (C) Biological activity of
the indicated Rev proteins as analyzed by provirus rescue assay. HeLa
cells were transiently cotransfected with the Rev-deficient proviral DNA
pHXB2Drev, the indicated Rev vectors and the internal control plasmid
pBC12/CMV/SEAP. The culture supernatants were collected at 48 h
post-transfection and virus particle release was determined by p24
Gag
antigen ELISA. All p24
Gag levels were adjusted to the SEAP activity
detected in each culture (transfection control).
doi:10.1371/journal.pone.0038305.g003
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Transcripts
Next we set out to identify distinct Rev activities that depend on
the oligomerization of Rev. Since Rev has been reported to affect
the stability of viral mRNA, we first examined the effect of Rev
and sealected Rev mutants on the half-life of RRE-containing
messages by employing the transcriptional pulsing approach using
the tetracycline-regulated promoter system [68]. This experimen-
tal system allows assessment of the stability of specific mRNA in
the absence of general transcription inhibitors such as actinomycin
D, a drug that can interfere with nucleocytoplasmic shuttling [69].
HeLa-tTA cells constitutively expressing the tetracycline-sensi-
tive trans-activator (tTA) were transiently transfected with a de-
rivative of the HIVDrev proviral DNA (pUHC- HIVDrev), in which
the viral 59-LTR was replaced by the tTA-responsive promoter,
thereby allowing doxycycline-induced transcriptional shutoff. As
detected by real-time PCR, env and more pronounced gag
transcripts were more abundant in RevWT coexpressing cells
(Figure 6A). Only residual amounts of gag and env mRNA copies
were detected when the culture supernatant was supplemented
with 100 ng/ml of doxycycline. A parallel experiment in which
p24
Gag antigen levels were monitored in the supernatants of the
transfected cultures demonstrated the expected phenotypes,
particularly RevWT- and ZipRevSLT40-dependent HIV-1 parti-
cle release in absence of doxycycline treatment (Figure 6B).
Finally, upon transcriptional shutoff the quantification of gag
sequences revealed, as previously reported [10,11], Rev-dependent
stabilization of these gag transcripts. Overall, gag mRNAs were
differentially stabilized by various Rev proteins. However, the
ability of Rev to form oligomers clearly did not correlate with Rev-
mediated mRNA stabilization (Figure 6C). Thus, failure of Rev to
form protein:protein oligomers does not significantly affect the
stability of Rev-regulated transcripts and can therefore not explain
the observed inactivity of RevSLT40 in the more general trans-
activation assays (Figure 3).
To directly analyze the nuclear export ability of RevSLT40 and
ZipRevSLT40, standard heterokaryon assays were performed, in
which transiently transfected human HeLa cells (expressing the
various Rev proteins) were fused with untransfected mouse NIH
3T3 cells to form heterokaryons. Fixed cells were analyzed by
Figure 4. FRET measurement of Rev oligomer formation. (A) Expression level and trans-activation capacity of Rev-CFP and Rev-YFP fusion
proteins. COS cells were transiently cotransfected with the Rev reporter plasmid pGPV-RRE and the indicated trans-activator constructs. At 24 h post-
transfection Rev-dependent expression of HIV-1 structural proteins p55
Gag and p24
Gag, the respective Rev trans-activators and actin (gel loading
control) was detected by Western blot analysis using specific antibodies. (B) Representative FACS plots illustrating the percentage of FRET positive
cells. COS cells were transiently transfected with expression vectors for control CFP and RevWT-YFP, or the indicated combinations of Rev donor and
acceptor constructs. To provide RRE RNA the plasmid pGPV-RRE was included in each transfection. At 24 h post-transfection cells were harvested and
analyzed by flow cytometry for Rev:Rev interaction, represented as FRET positive cells. (C) Mean percentage of FRET-positive cells (adjusted to the
background) determined in FRET-FACS experiments.
doi:10.1371/journal.pone.0038305.g004
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bodies. The respective cultures were also treated with Hoechst
33258 dye, which allows discrimination of human and mouse
nuclei (the latter are characterized by a typical speckle pattern).
Clearly, RevWT protein was able to migrate from the human to
the mouse nucleus in these experiments (Figure 7, panel a–c). As
expected, exposure of the cell culture to leptomycin B (LMB),
a highly specific small-molecular weight inhibitor of the CRM1
nuclear export receptor [70,71], abolished Rev’s ability to exit the
human nucleus (Figure 7, panel d–f). A comparable result was also
observed in a control experiment when the export-deficient
mutant RevM10 was analyzed (Figure 7, panel s–u). Interestingly,
both the oligomerization- and trans-activation-deficient mutant
RevSLT40, as well as the ZipRevSLT40 protein, displayed
comparable CRM1-dependent nuclear export activities in this
type of assay (Figure 7, panel g–l and panel m–r, respectively).
These data suggested that, in absence of RRE RNA, oligomer-
ization of Rev is not required for nuclear export of Rev proteins
via the CRM1-pathway.
Rev-dependent nucleocytoplasmic distribution of RRE-contain-
ing mRNA was next monitored by using two different experi-
mental designs. First, COS cells were transiently cotransfected
with the Rev-responsive reporter construct pDM128/CMV and
various Rev expression plasmids. At 48 h post-transfection nuclear
Figure 5. Regulated homodimerization of HIV-1 Rev. (A)
Expression of FKBP-Rev fusion constructs. HeLa cells were transiently
transfected with plasmids expressing the indicated Rev fusion proteins.
Levels of protein expression were determined by Western blot analysis
at 48 h post-transfection using specific anti-Rev and anti-actin (gel
loading control) antibodies. (B) Trans-activation capacity of Rev fusion
proteins. A provirus rescue assay was performed by transient
cotransfection of HeLa cells with pHXB2Drev DNA, the internal control
plasmid pBC12/CMV/SEAP and the indicated Rev expression vectors in
the absence or presence of the chemical homodimerizer AP20187.
Culture supernatants were collected at 48 h post-transfection and the
accumulation of HIV-1 particles was quantified by p24
Gag antigen ELISA.
Values of p24
Gag antigen were adjusted for transfection efficiency to
SEAP activity in each culture supernatant.
doi:10.1371/journal.pone.0038305.g005
Figure 6. Half-life determination of Rev-regulated transcripts.
(A) Expression of Rev-dependent gag (unspliced) and env (single
spliced) mRNAs in HeLa-tTA cells. HeLa-tTA cells were transiently
cotransfected with the Rev-deficient doxycyline-regulated proviral
construct pUHC-HXB2Drev and Rev expression plasmid or the parental
control vector pBC12/CMV. Transcription of viral RNA was blocked
where indicated by 100 ng/ml doxycycline treatment at 5 h post-
transfection. Subsequently, the viral RNA levels were quantified at 24 h
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cultures and analyzed by quantitative S1 nuclease protection
analyses. The endlabelled input probe allowed its discrimination
from unspliced and spliced reporter mRNA (depicted in
Figure 8A). Inspection of the obtained data revealed that the
oligomerization-defective mutant RevSLT40 failed to mediate
efficient cytoplasmic accumulation of unspliced mRNA
(Figure 8B). Obviously, nuclear export of these RRE-containing
transcripts was restored when the ZipRevSLT40 fusion protein
was coexpressed, indicating that oligomer-formation of Rev is
required for the translocation of Rev-regulated transcripts across
the nuclear envelope.
These results were confirmed in an independent and more
quantitative assay. HeLa cells were again contransfected with the
full-length proviral DNA HIVDrev together with selected Rev
expression vectors. Unspliced gag-specific messages were sub-
sequently detected by quantitative real-time PCR in cytoplasmic
and nuclear RNA, isolated from the transfected cultures at 48 h
post-transfection. The fractionation method was controlled by
detection of the nuclear U6 snRNA using a slot-blot device (not
shown). This analysis also demonstrated pronounced cytoplasmic
accumulation of HIV-1 gag mRNA in a Rev-dependent fashion
(Figure 8C). In agreement with the data raised above, RevSLT40
was incapable of mediating the nuclear export of gag-specific
transcripts while, in sharp contrast, fusion of the GCN4 leucine
zipper to RevSLT40 clearly restored this Rev-specific activity.
Furthermore, control experiments in which the cotransfection of
a Rev expression vector was omitted, or in which nuclear export-
deficient RevM10 protein was expressed, resulted in the expected
negative phenotype (Figure 8C).
In sum, these data demonstrate that oligomerization of Rev is
essential for Rev-mediated nuclear export of RRE-containing viral
transcripts.
Rev Trans-activation Requires Multiple Activation
Domains
To address the question of whether Rev has to oligomerize in
order to recruit multiple NES-containing protein activation
domains onto the RRE RNA, another version of the ARGENT
dimerization kit (ARIAD Pharmaceuticals) was used. This system
employs a specific cell permeant heterodimerizer molecule, the
rapamycin analog AP21967, which allows the dimerization of two
different proteins when they are attached to appropriate binding
domains. Therefore, various Rev encoding sequences were fused
to engineered versions of either the FKBP motif (e.g. N1-Rev) or
a domain of the PI3K homolog FRAP (e.g. RH-Rev). Rev protein
expression by these constructs was subsequently confirmed by
transient transfection of COS cells and Western blot analysis
(Figure 9A). The transfection of matched pairs of these expression
vectors also allowed the formation of Rev heterodimers when the
culture medium was supplemented with AP21967. In addition,
inclusion of the Gag-expressing GPV-RRE reporter vector into
the transfection protocol permitted monitoring of Rev activity. As
shown, the fully oligomerization competent RevWT protein
displayed the highest activity in this assay, while homooligomers
formed by the nuclear export-deficient mutant RevM10 were, as
expected, completely inactive (Figure 9B). Interestingly,
RevSLT40 homodimers, as well as heterodimers formed by the
oligomerization-defective mutant RevSLT40 and RevM10 were
to a certain extent also active. The latter result can be explained by
RevM10’s remaining intrinsic capacity to form homomultimers
[33,55]. Thus, in presence of the heterodimerizer molecule, higher
order RH-RevM10 complexes may recruit additional N1-
RevSLT40 proteins (and thereby functional activation domains;
depicted in Figure 9C). Therefore, the double mutant
RevSLT40M10 was also included in these analyses. Clearly,
heterodimers composed of N1-RevSLT40 and RH-
RevSLT40M10 were completely devoid of any biological activity
in these experiments (Figure 9B), indicating that at least two
activation domains are required for Rev-mediated trans-activation.
Discussion
The translocation of unspliced and incompletely spliced viral
RNAs, from their nuclear site of transcription to the cytoplasm,
the site of translation and virus assembly, is mediated by the Rev
trans-activator protein [9–12]. In the nucleus, Rev directly
recognizes viral RNA via the cis-acting RRE sequence, multi-
merizes, and interacts with CRM1 for subsequent nuclear exit of
the Rev-bound transcripts (reviewed in [1,72,73]). Accordingly, in
recent years a large body of studies focused on Rev’s RNA binding
properties and, particularly, on its role in nuclear export. In
comparison, relatively little attention was focused on Rev’s
capacity to form homooligomeric complexes on the RRE and
the role of this process in Rev trans-activation.
In this study, by employing various Rev trans-activation assays,
including assays measuring Rev-dependent HIV-1 particle release,
we were able to provide evidence that multimerization of Rev on
the RRE is required for nuclear export of Rev-regulated viral
mRNA. Importantly, this was demonstrated by an experimental
gain-of-function approach that allowed the recording of positive
and therefore meaningful results. The fusion of heterologous
dimerization motifs to the oligomerization-deficient mutant
RevSLT40 restored not only trans-activation in the respective
assays (Figure 3), but also reconstituted Rev-mediated nuclear
mRNA export, which was reflected by Rev dimerization-de-
pendent cytoplasmic detection of RRE-containing transcripts
(Figure 8). These data are in agreement with a previous study
that reported that oligomerization of Rev is important for nuclear
export of Rev:RRE complexes [56]. However, the evidence
supporting this notion was based on negative data (i.e. loss-of-
function) using a single reporter construct whose readout is
sensitive to many of Rev’s established activities (e.g. RNA
stabilization, nuclear export, translation) and no direct RNA
transport data were provided. Moreover, other previous studies,
proposing that multimerization-deficient Rev mutants are de-
fective in the nuclear export of unspliced RRE-containing mRNAs
[19,33] employed the RevM4 mutant, that is, as outlined before,
characterized by an inconsistent oligomerization phenotype
[33,55]. Therefore, by using the multimerization deficient mutant
posttransfection by real-time PCR. Results for viral RNA copies were
adjusted to the level of endogenous gapdh mRNA. (B) Inhibition of
replication by doxycycline treatment. HeLa-tTA cells were transiently
cotransfected with pUHC-HXB2Drev, pBC12/CMV/SEAP (internal con-
trol) and the indicated Rev constructs. The accumulation of p24
Gag
antigen in the culture supernatants was quantified by ELISA at 48 h
post-transfection. All values were adjusted for transfection efficiency to
the SEAP activity present in each supernatant. Viral expression was
blocked when the culture medium was supplemented with 100 ng/ml
doxycycline. (C) Effect of the indicated Rev mutants on the half-life of
unspliced full-length (gag) HIV-1 RNA. Transfection experiments were
performed in HeLa-tTA cells using pUHC-HXB2Drev DNA and the
indicated trans-activator constructs. Total RNA was isolated and viral
gag RNA copy numbers were quantified after transcriptional pulse at
the indicated time points by real-time PCR and adjusted to the
endogenous gapdh mRNA level in each sample. The relative RNA levels
are show in comparison to the respective initial level (after
transcriptional pulse) at time point 0 h (set to 1.0).
doi:10.1371/journal.pone.0038305.g006
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PLoS ONE | www.plosone.org 8 June 2012 | Volume 7 | Issue 6 | e38305RevSLT40 [34], the data obtained in the present study provide to
our knowledge the so far most definitive experimental evidence
that multimer-formation of Rev is essential for nuclear export of
Rev-containing RNP complexes.
Clearly, dimer induction by fusion of heterologous dimerization
motifs to the amino terminus of the otherwise multimerization-
deficient mutant RevSLT40 could not have been expected to
restore Rev activity to its full extent. Nevertheless, trans-activation
activity was routinely restored to levels ranging from 40% to 68%
of Rev wildtype activity, depending on the assay used (see Figure 3
and 5). This is in good agreement with our quantitative FRET
measurements (Figure 4), in which co-expression of CFP and YFP
labeled ZipRevSLT40 resulted in a dimerization capacity of about
52% when compared to the wildtype protein (RevWT: 80.3%
FRET positive cells; ZipRevSLT40:41.9% FRET positive cells).
Although in our experiments the formation of a Rev dimer was
sufficient to drive to a detectable extent virus replication, it is still
unknown how many Rev molecules have to be assembled on the
RRE for maximal activity. A large body of previous biochemical
and cell-based studies resulted in a model of Rev:RRE interaction,
in which the initial binding of a Rev monomer to the SLIIB high-
affinity binding site triggers the recruitment of additional Rev
monomers by cooperative Rev:Rev interaction, resulting in the
occupation of secondary low-affinity sites in the RRE
[41,49,50,74]. Careful protein titration studies in combination
with functional assays indicated already previously that two
monomeric Rev proteins bound to the RRE results in measurable
biological activity [75]. Similar data were also reported in an
independent functional study using a heterologous Rev-responsive
reporter construct. Considerable Rev activity was observed when
the RRE was replaced by phage MS2 operator RNA and Rev was
expressed as fusion to MS2 coat protein [76]. Apparently, upon
RNA binding the Rev/MS2 protein dimerized via its MS2 moiety
[77], resulting in Rev trans-activation. Rev activity then further
increases with the number of Rev molecules that are recruited
onto the RRE [33,41]. Importantly, this sequential model of
Rev:RRE interaction has been recently confirmed and refined by
employing single-molecule fluorescence spectroscopy, directly
demonstrating that Rev indeed assembles on RRE RNA one
molecule after another [52].
HIV-1 Rev trans-activation induces the transit from the early
phase to the late phase of viral mRNA expression, a process that
depends on Rev’s nuclear mRNA export activity [1,72,73]. The
transport of Rev-containing RNP complexes across the nuclear
envelope is mediated by the cellular export receptor CRM1 and
associated factors [29–32]. CRM1 generally mediates the nuclear
export of non-coding RNA, ribosomal subunits and numerous
proteins and therefore specifies a rather uncommon route for the
nuclear export of mRNA [78,79]. By using the highly specific
CRM1 inhibitor leptomycin B [70,71], the analysis of Rev
shuttling clearly demonstrated nuclear export of the oligomeriza-
tion-deficient RevSLT40 protein via the CRM1 pathway
(Figure 7). In contrast, however, RevSLT40 was unable to
mediate the export of RRE-containing transcripts, an activity that
was restored by dimer formation (Figure 8). This finding may
suggest that a single CRM1 molecule is sufficient to mediate the
nuclear export of a monomeric Rev protein in absence of RRE
RNA-binding. However, multiple Rev proteins and, due to Rev
NES:CRM1 interaction [80], possibly an equivalent number of
CRM1 molecules have to be recruited onto RRE-containing
transcripts for their efficient nucleocytoplasmic translocation.
Clearly, this notion is in agreement with the results obtained by
using Rev heterodimers, suggesting that at least two Rev NES are
required for the formation of an export-competent Rev:RRE
complex (Figure 9).
A somewhat alternative interpretation of the presented data
may be that Rev oligomerization on the RRE is not only
important for recruitment of multiple CRM1 proteins, but also
provides a binding platform for the recruitment of additional host
factors that facilitate the nuclear export of RRE-containing
transcripts. Among others the most likely candidates for such
Rev cofactors are some RNA helicases, particularly the DEAD
box protein 1 (DDX1) [81], the human Rev-interacting protein
(hRIP) [82,83], eukaryotic initiation factor 5A (eIF5A) [84,85],
and Src-associated protein in mitosis of 68 kDa (Sam68) [86,87].
Multiple lines of evidence demonstrated that these host factors
directly or indirectly interact with Rev and critically participate in
the posttranscriptional processing of Rev-regulated mRNA
(reviewed in [88–91]). Importantly, by employing total internal
reflection fluorescence (TIRF) microscopy, a recent study demon-
strated that particularly the DEAD box protein DDX1 promotes
Rev oligomerization on the RRE [92]. Thus, the formation of
homooligomeric Rev complexes on the RRE is not only facilitated
by cellular proteins such as DDX1, but may also be a precondition
for the recruitment of one or more of the host factors mentioned
above into nascent Rev-containing RNP.
In sum, the data presented here directly demonstrate that Rev
oligomerization on the RRE, and thereby the recruitment of
multiple NES-containing Rev activation domains, is required for
nuclear export of unspliced and incompletely spliced viral RNA.
Because Rev-mediated RNA export is essential for virus replica-
tion, the interference with Rev activity [90,93], for example by
blocking Rev’s capacity to self-associate on the RRE, may




The plasmids pcRev and pcTat contain the cDNA of the
retroviral genes derived from HIV-1 strain HXB3 and have been
described elsewhere [94]. The parental vector pBC12/CMV was
used as a negative control in all transfections [95]. The trans-
dominant mutants pcRevSLT40 and pcRevM10 have been
described previously [19,34]. The pcZipRevSLT40 construct
was generated by inserting the cDNA from the yeast GCN4
leucin zipper motif (NH2-MDPKLQRMKQLEDKVEELLS-
KNYHLENEVARLKKLVGG-COOH) [62,63] at the 59 end
into the reading frame of the RevSLT40 cDNA. The constructs
expressing Tat-Rev fusion proteins pcTat/Rev, pcTat/RevM5,
pcTat/RevM10 and pcTat/RevSLT40 have been described in
detail elsewhere [34,55]. The plasmid encoding for Tat-
ZipRevSLT40 was constructed by inserting the leucine zipper
Figure 7. Nucleocytoplasmic shuttling of Rev. Standard interspecies heterokaryon fusion assay for detection of protein nuclear export. HeLa
cells were transiently transfected with the indicated Rev expression plasmids and fused at 24 h post-transfection with untransfected NIH3T3 cells
(indicated by an asterisk). CRM1-mediated protein shuttling was blocked by treatment of the cultures with leptomycin B (LMB). Localization and
nuclear export of Rev proteins was visualized by indirect immunofluorescence microscopy using specific anti-Rev antibody (red label; panel b, e, h, k,
n, q, t). Nuclei were stained with Hoechst 33258 (blue label; panel a, d, g, j, m, p, s) and merged with the fluorescence and bright light pictures (panel
c, f, i, l, o, r, u).
doi:10.1371/journal.pone.0038305.g007
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PLoS ONE | www.plosone.org 9 June 2012 | Volume 7 | Issue 6 | e38305Figure 8. Analysis of Rev-mediated nuclear RNA export. (A) Schematic representation of the nuclease S1 protection assay. The Rev reporter,
the end-labelled input probe and the protected sequences, recognizing unspliced and spliced RNA are depicted. (B) Nucleocytoplasmic distribution
of Rev-regulated unspliced and spliced RNA determined by nuclease S1 assay. COS cells were transiently cotransfected with Rev reporter DNA
pDM128/CMV and the indicated Rev expression vectors. Nuclear and cytoplasmic RNA was isolated at 48 h post-transfection. Unspliced and spliced
reporter-derived RNA was detected by autoradiography using the
32P-labeled input probe. (N, nuclear RNA; C, cytoplasmic RNA). (C) Quantification of
Rev-regulated cytoplasmic and nuclear viral RNA. HeLa cells were transiently cotransfected with pHXB2Drev and the indicated Rev constructs. At 48 h
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RevSLT40M10 expression constructs were generated by in-
troducing the RevM10 (LE 78,79 DL) mutation into the
RevSLT40 cDNA by using PCR site-directed mutagenesis. The
plasmids encoding for the regulated dimerization proteins FKBP-
Rev and FKBP-RevSLT40 were constructed by inserting the
cDNA of the homodimerization motifs from the plasmid pC4-
Fv1E (ARIAD Pharmaceuticals) at the 59-end into the reading
frame of respective Rev expression plasmids. The expression
plasmids encoding for N1- and RH-Rev fusion proteins were
generated by subcloning the heterodimerization motifs from the
parental vectors pC4EN-F1E and pC4-RHE (ARIAD Pharmaceu-
ticals) into the respective Rev expression plasmids. The RRE RNA
binding reporter plasmid pCAT/SLIIB contains a LTR promoter
in which the trans-activator response element (TAR) was replaced
by the Rev primary binding site, stem loop II, derived from the
Rev response element (RRE) [64]. The plasmids pDM128/CMV
[21,26], pGVP-RRE [67] and the proviral construct pHXB2Drev
[96] are previously established Rev reporter constructs. The
doxycycline-regulated pUHC-HXB2Drev expression plasmid was
generated by replacing the viral 59-LTR promoter through the tet-
off promoter derived from the pUHD13-3 plasmid [97]. The
expression plasmids pBC12/CMV/b-Gal and pBC12/CMV/
SEAP were used for internal transfection control [98,99]. The
constructs encoding for Rev-CFP and Rev-YFP fusion proteins
were generated by fusing the respective Rev cDNAs in-frame to
the 59 end of the fluorescent protein coding region in the parental
vector pECFP-N1 and pEYFP-N1 (Clontech) [66].
Cell Culture, Transfections, and Assays
HeLa (ATCC Cat.# CCL-2), HeLa-tTA [97] (obtained from
Prof. Wolfgang Hillen, University Erlangen-Nu ¨rnberg) and COS
(ATCC Cat.# CRL-1650) cells were cultured in Dulbecco’s
modified eagle medium (DMEM) supplemented with 10% fetal
bovine serum and were transiently transfected either with
TurboFect (Fermentas) or TransIT (Mirrus) according to the
manufacturers’ protocol or with DEAE dextran as previously
published [64]. Routinely, 2610
5 cells were transfected with
500 ng reporter plamid (pDM128/CMV, pSLIIB/CAT, pGPV-
RRE, pHXB2Drev or pUHCHXB2Drev, respectively), 250 ng Rev
construct and 125 ng plasmid DNA for internal transfection
control (pBC12/CMV/SEAP or pBC12/CMV/b-Gal). At 48 h
post-transfection, culture supernatants were removed and ana-
lyzed for particle release by p24
Gag antigen ELISA (Innogenetics
NV) and adjusted to the secreted alkaline phosphatase (SEAP)
level (internal transfection control). Cell pellets were harvested by
trypsin and cell extracts were prepared using E1A lysis buffer
(50 mM Hepes pH 7.5, 150 mM NaCl, 1% NP-40). Western blot
analyses were performed by using anti-HIV-1 p55
Gag specific
antibodies (NIH AIDS), specific anti-Rev specific antibodies [20],
anti-tubulin (Sigma), anti-GAPDH (Santa Cruz) and anti-actin
(Sigma). Reporter expression of pDM128/CMV and pSLIIB/
CAT was measured with the CAT ELISA Kit (Roche) in
accordance to the manufacturer’s protocol. The CAT expression
levels were adjusted to the expression level of the internal
transfection control b-Gal. To induce the regulated dimerization,
500 mM of AP20187 (ARIAD Pharmaceuticals) for homodimer-
ization and 500 mM of AP21967 (ARIAD Pharmaceuticals) for
heterodimerization was added 5 h post-transfection by exchanging
the culture media. For FACS-based FRET analyses, 5610
5 COS
cells were transiently transfected with 500 ng of the various Rev
acceptor and donor constructs together with 500 ng of the pGPV-
RRE reporter. Western blot analyses and FACS measurement
were performed 36 h posttransfection. For heterokaryon assays,
2610
5 HeLa cells were transiently transfected with 1 mg of the
respective Rev expression plasmids.
FACS-FRET
For analyses of Rev-Rev interactions, FRET signals of COS
cells, transfected with Rev donor and acceptor plasmids, were
measured with the FACSAria system (BD Bioscience) using the
405 nm and 488 nm laser lines as previously described [66]. The
CFP-positive COS cells were excited with the 405 nm laser and
fluorescence was analyzed in the CFP channel by using the
standard 450/40 filter (Semrock). YFP positive cells were excited
with the 488 nm laser and measured with the 529/24 filter
(Semrock). The FRET-positive cells were monitored by 488 nm
excitation and signal emission was detected with the 529/24 filter
in the YFP channel. For each sample at least one thousand CFP/
YFP positive cells were analyzed, and signals were adjusted to the
background.
RNA Isolation and PCR
Total cellular RNA was isolated with the TriFAST system
(PeqLab) according to the manufacturer’s protocol. For the
isolation of cytoplasmic and nuclear RNA cells were fractionated
into the subcellular compartments by using Nonidet-P40 buffer
(10 mM Hepes pH 7.8, 10 mM KCl, 20% glycerin, 0.25%
Nonidet-40 and 1 mM DTT) as described before [100]. To
remove DNA plasmid contaminations, samples were treated with
1 U DNase (Promega) and subsequently RNA was phenol/
chloroform/isoamyl alcohol extracted. For analyses of viral RNA
distribution and total RNA expression, 1 mg of RNA was reverse
transcribed using the M-MLV reverse transcriptase (Promega) and
poly dT primer in accordance with the manufacturer’s protocol.
For the quantification of viral RNA, corresponding cDNAs were
used for real-time PCR analyses. Copies of viral RNA were
determined by using a plasmid standard. The viral RNA copies
were adjusted to the cellular gapdh RNA level. The following
oligonucleotides and Taqman probes were used for RNA de-
tection: gag/env forward, 59–GCAGGACTCGGCTTGCTGAA–
39; gag reverse, 59–AGGATTAACTGCGAATCG TTCTA–39;
gag probe, 59–(FAM)–TTGACTAGCGGAGGCTAGAAG-
GAGA–(TAMRA)–39; env reverse, 59–GCTACTACTAATGC-
TACTATTGCT–39; env probe, 59–(FAM)–ATAGAGAAGCTT-
GATGAGTCTGACTGTT–(TAMRA)–39; gapdh forward, 59-
GTCATC AATGGAAATCCCATCA-39; gapdh reverse, 39-
TGGTTCACACCCATGACGAA-59; gapdh probe, 59-(FAM)-
TCTTCCAGGAGCGAGATCCCTC-(TAMRA)-39. Nuclease
S1 protection assay was performed as described elsewhere [98].
The radiolabeled probe includes the HIV-1 splice site derived
from the pDM128/CMV plasmid [21] and heterologous non-HIV
sequences to distinguish between the input probe and the
unspliced as well as the spliced RNA-DNA hybrids.
RNA Stability Measurements
For analyses of the influence of Rev mutants on the stability of
viral RNA, HeLa-tTA cells were transiently transfected with the
doxycycline-regulated construct pUHC-HXB2Drev and the re-
post-transfection nuclear and cytoplasmic RNAs were isolated and the accumulation of Rev-regulated unspliced gag RNA was quantified by real-time
PCR. Total viral copy numbers were adjusted to the endogenous gapdh mRNA level in each sample.
doi:10.1371/journal.pone.0038305.g008
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the pUHC-HXB2Drev construct, HeLa-tTA cells were cultured
5 h post-transfection with 100 ng/ml doxycycline. At 24 h
posttransfection total RNA was isolated and the copies of viral
unspliced gag RNA and single-spliced env RNA was quantified by
real-time PCR. To determine the half-life of viral gag RNA in the
presence of Rev mutants, the transcriptional pulsing strategy was
employed [68]. Therefore transiently transfected HeLa-tTA cells
were incubated with 100 ng/ml doxycycline and reporter RNA
transcription was blocked over night. On the next day the
transcriptional pulse was induced by changing the media to fresh
DMEM lacking doxycycline for additional 4 h of culturing. Viral
RNA transcription was stopped by treating the cultures with
various concentrations of doxycycline. Total cellular RNA was
isolated at time points 0, 1, 2, 4, 6, 10, 16, 20 and 24 h, and gag
RNA expression was quantified by real-time PCR.
Heterokaryon Assay
To analyze the nucleocytoplasmic shuttling of Rev, 6610
4
HeLa cells, transiently transfected with various Rev expression
plasmids, were cocultured at 24 h post-transfection with 8610
4
murine NIH3T3 cells (ATCC Cat.# CRL-1658) on coverslips.
The next day, protein expression was blocked by using 100 mg/ml
cycloheximide and 20 nM leptomycin B (LMB) to inhibit CRM-1
specific nuclear export. Cell fusion was performed by using
PEG1500 (Roche) according to the manufacturer’s protocol and
cells were cocultured in cycloheximide- and LMB-containing
medium for an additional hour. Rev protein shuttling was
monitored by indirect immunofluorescence microscopy.
Immunofluorescence Microscopy
To analyze the nucleocytoplasmic shuttling of Rev mutants,
human:mouse hybrid cells were grown on coverslips and fixed
with 4% paraformaldehyde. Subsequently, cells were permabilized
with 0.1% Triton X-100 and stained with a mouse monoclonal
anti-Rev antibody, followed by a Cy3-conjugated anti-mouse
antibody [20]. Nuclei were visualized by Hoechst 33258 staining.
The cells were mounted in mowiol medium and analysed using
a Zeiss Axiovert-200 M microscope.
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